

Instruction for use Insulin-like Growth Factor I Kit (Microfluidic Fluorescent Immunoassay)

Product name

Insulin-like Growth Factor I Kit (Microfluidic Fluorescent Immunoassay) Abbreviated name: LYOFIA IGF-I

Ref. No. --- Package size

LMGDIG25C --- 25 Tests, LMGDIG25 --- 25 Tests (N-QC)

Package size

100 Tests, 50 Tests, 25 Tests, 10 Tests, 5 Tests, 100 Tests (N-QC), 50 Tests (N-QC), 25 Tests (N-QC), 10 Tests (N-QC), 5 Tests (N-QC).

Intended use

This device is intended to be used for the in vitro quantitative determination of insulin-like growth factor I (IGF-I) in human whole blood, serum or plasma. And it is for professional use only, not for self-testing of untrained individuals, nor for near-patient testing.

Summary

Insulin-like growth factor 1 (IGF-1) is a class of polypeptides belonging to the insulin family. IGF-I was isolated and purified from plasma. It consisted of 70 amino acids, had 43% homology with the amino acid sequence of proinsulin, and had a molecular weight of 70 kDa. The human IGF-I gene is located in the 2-4 band (12q11-24) of staining region 12, and contains 5 exons ^[1]. Its biological activity is regulated by IGF-I receptor and insulin-binding protein. It can promote cell differentiation, stimulate RNA and DNA synthesis and cell proliferation, promote cell mitosis and the expression of differentiation functions, and promote lipid and Glycogen and protein synthesis ^[2]. Body levels of IGF-1reflect endogenous growth hormone secretion, and IGF-1 is a kind of marker which can be used to detect the deficiency and excess of growth hormone ^[3].

The current clinical methods for detecting IGF-I include chemiluminescence, immunochromatography and so on.

Principle

This product adopts the microfluidic fluorescence immunoluminescence method. The luminescent material relies on the external light source to obtain energy, then it is excited to make luminescence. And the immunological principle used is double antibody sandwich method. In addition, the microstructure in the strip inside the test cassette can make the reaction system to be uniformly mixed inside the test cassette, thereby improving the accuracy and precision of the detection result.




Figure 1: Schematic diagram of the test cassette

As shown in Figure 1, below the sample well is the lyophilized spheres placement tank. The lyophilized spheres are contained in the tank. The main component of the lyophilized sphere is the nanosphere (containing luminescent material) which is coupled with IGF-I monoclonal antibody I and Chicken IgY antibody. The main component of T line is IGF-I monoclonal antibody II, and the main component of C line is Goat anti-chicken IgY antibody.

The sample added from the sample well enters the flow microchannel through the microchannel valve and the microchannel mixer valve, so that the lyophilized spheres and the specimen in the lyophilized spheres placement tank are quickly dissolved and mixed evenly. The sample mixture flows along the microfluidic channel to the reaction chamber for reaction. The antigen in the specimen reacts with IGF-I monoclonal antibody I to antigen-antibody-nanosphere form an complex. The antigen-antibody-nanosphere complex will flow forward along the nitrocellulose membrane through the sample pad and can be captured by the IGF-I monoclonal antibody II immobilized on the T line of the nitrocellulose membrane to form a double-antibody sandwich complex. In addition, the Chicken IgY antibody in the reaction system can be captured by the Goat anti-chicken IgY antibody immobilized on the C line. The more antigen in the sample, the more complexes will accumulate on the T line. The intensity of the fluorescent signal reflects the amount of captured antigen.

The fluorescence immunoassay analyzer used with the kit emits emission light, irradiates the T line and the C line, and excites the nanospheres to emit light, and then the specific signal values of the T line and the C line can be obtained.

The content of IGF-I in the sample can be determined using the calibration curve served in the Reagent information carrier.

	Components	and	ingred	ients
--	------------	-----	--------	-------

No.		Main components and ingredients		
		Upper layer microfluidic		
1	chip Test		Blocking lyophilized spheres	Mouse IgG
1	Cassette	Sample pad		
		(containing membrane test strip)	Nitrocellulose	IGF-I monoclonal antibody II
				Goat anti-chicken IgY antibody
			Abso	rbent paper
		PVC base plate		base plate
2	Sample	Tris buffer Proclin300		r
	Diluent			
3	Reagent information carrier	A calibration curve is stored. The detection system is traceable to certified reference materials.		
4	Control	Level 1IGF-I antigenLevel 2IGF-I antigen		-I antigen
-	Control			

Note:

Sample Diluent (see the packaging label for the quantity);

> The kit whose packaging specifications describes "(N-QC)" do not contain quality control products;

> See the "target value list" for the target value range of the quality controls;

> The components from different lots of kits cannot be interchanged or mixed.

Storage and stability

Store the product at $2 \sim 30^{\circ}$ C, it has a validity period of 18 months. Once the aluminum foil pouch of the test cassette is opened, the cassette has a validity period of 24 hours. After the control solution is reconstituted, seal and store it at $2 \sim 8^{\circ}$ C with a validity period of 4 hours. Do not use the test kit beyond the expiration date as indicated on label.

Applicable analyzer

Fluorescence immunoassay analyzer manufactured by Hunan Kangxin Biotechnology Co., Ltd., model LYOFIA-I, LYOFIA8.

Specimen requirements

1. This product is suitable for serum, plasma and whole blood samples. Lithium heparin and sodium heparin for plasma and whole blood samples. The other anticoagulants have not been validated, they may affect the test results.

2. It is recommended that finishing the testing of whole blood, serum and plasma immediately. If the specimens specified above cannot be used at once, store them at $2\sim8^{\circ}$ C and finish the testing within 12 hours or store the specimens for up to 1 months at $-20\pm5^{\circ}$ C. Whole blood and plasma should not be frozen.

3. The samples to be tested should be free of precipitation. If



Instruction for use

Insulin-like Growth Factor I Kit (Microfluidic Fluorescent Immunoassay)

precipitation occurs, centrifugation must be performed first. Do not use heat-inactivated samples.

4. Equilibrate the samples to ambient temperature before measurement. Cryopreserved samples should be completely thawed, rewarmed, and evenly mixed before use. Multiple freeze-thaw cycles should be avoided. Do not use samples with significant hemolysis or blood clots.

Assay procedure

1. Assay preparation

1.1 Please follow this instruction for use and refer to the instruction manual of the fluorescence immunoassay analyzer.

1.2 Turn on the fluorescence immunoassay analyzer, check whether the analyzer can work normally, and prepare other related consumables.

1.3 Equilibrate the aluminum foil pouch to ambient temperature before opening.

1.4 Equilibrate the sample diluent and specimens to ambient temperature.

2. Calibration

Insert the reagent information carrier into the interface for the reagent information carrier on the analyzer LYOFIA-I or LYOFIA8, import the calibration curve stored in the reagent information carrier into the analyzer, and check whether the batch number of the reagent information carrier and the kit are consistent. Refer to the analyzer manual for specific operations. 3. Sample testing

3.1 Take out the test cassette has been equilibrated to ambient temperature and place it horizontally on a flat surface.

3.2 Dilute the sample with the sample diluent at the ratio of 1:3 (recommended procedure: pipette 65μ L of sample into a centrifuge tube with 195μ L of sample diluent). After mixing, take 65μ L of the liquid and quickly add it into the sample well of the upper layer microfluidic chip (the small hole pointed by the arrow on the upper layer microfluidic chip). It is recommended to aspirate and dispense rapidly 3 times in the cassette hole.

3.3 Incubation and testing according to applicable instruments, as follows:

3.3.1 If the measuring instrument is LYOFIA-I, please insert the test card into the incubator immediately after adding the sample and then to let it stand for 10 minutes for reaction. Remove the test cassette after the end of the reaction, and insert it into the right position of the fluorescence immunoassay analyzer LYOFIA-I, click the "Test" for testing, and the analyzer will automatically scan the test cassette.

3.3.2 If the measuring instrument is LYOFIA8, please insert the test card into the test slot immediately after adding the sample, LYOFIA8 will automatically scan the test cassette, time the reaction and automatically detect after the reaction is over.

3.4 The fluorescence immunoassay analyzer automatically detects the results and calculates the content of IGF-I in the sample.

3.5 Take out the test cassette used and dispose it as medical waste. Results Analysis

4. Results Analysis

The measured fluorescence signal value can directly read the content of IGF-I in the sample from the calibration curve stored in the reagent information carrier of the corresponding batch. The default detection result is in ng/mL.

5. Quality Control

Each laboratory shall establish its own quality control system and rules according to relevant requirements.

To conduct quality control, you must use the quality controls of the same batch of the kit. The quality control product is lyophilized. After returning to ambient temperature, reconstitute it with purified water (show the target list for the water volume required), let it stand for at least 15 minutes, shake it horizontally and mix well, and then test the reconstituted control solution as a sample.

Reference interval

60~350 ng/mL

It is recommended that each laboratory establish its own reference

interval because IGF-I level determined is varied depending upon geographical, individuals difference, or testing methods.

Result interpretation

The test results shall be only considered as a clinical reference rather than the unique basis for confirming or excluding a case. For diagnostic purposes, results should always be used in combination with clinical examination, medical history and other results of inspection.

Limitation

1. Possible causes of abnormal test results: Heterophilic antibodies, some non-specific components in blood with similar antigenic determinants can capture fluorescence-labeled antibodies.

2. Bacterial contamination of the sample or repeated freeze-thaw may affect the results.

3. Samples with IGF-I content close to or exceeding the upper limit of the linear range can be diluted with sample dilutent, and the maximum dilution ratio is 1:1. The upper limit of the reportable range after dilution is 2000 ng/mL.

4. Different brands and materials of blood collection tubes may affect the test results.

Performance characteristics

1. Limit of detection: Not higher than 20 ng/mL.

2. Linearity: Linear interval is [20, 1000] ng/mL; and the correlation coefficient |r| is not less than 0.9900.

Precision

3.1 Repeatability imprecision: The coefficient of variation (CV) is not more than 10%.

3.2 Within-laboratory imprecision: The coefficient of variation (CV) is not more than 10%.

3.3 Inter-lot imprecision: The coefficient of variation (CV) is not more than 15%.

4. Cross-reactivity: Testing the sample whose concentration of Insulin-like Growth Factor II is not less than 600 ng/mL, the measurement result using this kit is not higher than 20 ng/mL; Testing the sample whose concentration of Insulin is not less than 18000 μ IU/mL, the measurement result using this kit is not higher than 20 ng/mL.

5. Interference: Refer to the method of EP7-A2 "Interference Testing in Clinical Chemistry" to conduct the evaluation. If the relative deviation of the measurand value of the sample spiked with the interfering substance and that of the sample in absence of the interfering substance is not higher than 15%, the substance of no more than the corresponding study concentration may be considered no interference effect. Please see Table 1 for the upper limit of no interference of interfering substances to the assay:

Table 1: List of upper limits of no interference of interfering substances to the assav

substances to the assay		
Interference substance	upper limit of no interference to the assay	
Triglycerides	10 mg/mL	
Bilirubin	0.3 mg/mL	
Hemoglobin	6 mg/mL	
Rheumatoid factor	50 IU/mL	
Heterophilic antibodies	1:10	

6. HOOK effect: IGF-I samples with concentrations higher than 2500 ng/mL may have HOOK effect.

Precautions and warnings

1. This product is an *in vitro* diagnostic reagent for single use and must not be reused.

2. The treatment, use, storage of the specimens and kits' each component, and the disposal of solid and liquid wastes generated during the assay process should be handled in accordance with the corresponding measures of local biosafety guidelines or regulations.

3. Strictly follow operation procedure, and the correct result only be obtained under careful operation. Any modification to the operation procedure may affect the accuracy of the test results.

4. This product is sensitive to humidity, do not use if the foil pouch



Instruction for use Insulin-like Growth Factor I Kit (Microfluidic Fluorescent Immunoassay)

is damaged.

5. Do not insert the test cassette whose surface is wet with other liquids into the analyzer to avoid contamination and damage to the analyzer.

6. Keep away from vibration and electromagnetic environment when using the test cassette and fluorescence immunoassay analyzer.

7. Please see the outer label of the package of the kit for the production date and expiration date.

This product contains chemical ingredients. Contacting with skin or mucosa should be avoided. If the product is spilled into eyes, mouth or skin accidentally, rinse with running water and seek for doctor advice if necessary.

This product contains animal-derived substances. Although it has passed the biosafety test, it does not rule out the risk of other potential infections. Please consider the kit and samples as potential sources of infection, and wear disposable gloves or take other measures to reduce the risk of infection during the detection process.

Symbols for use in	n the labeling		
Symbols	Definition		
×	KEEP AWAY FROM SUNLIIGF-IT		
	TEMPERATURE LIMIT		
IVD	IN VITRO DIAGNOSTIC MEDICAL DEVICE		
) Here	CONSULT INSTRUCTIONS FOR USE		
LOT	BATCH CODE		
REF	CATALOG NUMBER		
M	USE-BY DATE		
\sim	DATE OF MANUFACTURE		
	MANUFACTURER		
Σ	SUFFICIENT FOR TESTS		
\otimes	DO NOT RE-USE		
\wedge	CAUTION		
*	KEEP DRY		
8	DO NOT USE IF PACKAGE IS DAMAGED		
	AUTHORIZED REPRESENTATITVE IN THE		
EC REP	EUROPEAN COMMUNITY		

Bibliography

[1] Ding Yanfeng, He Ruirong. The effect of insulin-like gro wth factor I on the heart [J]. Advances in Physiological Scie nce, 2000, 31(3): 234-236.

[2] Li Jinrong. Insulin-like growth factor I [J]. Medical Revie w, 2006, 12(7): 396-398. DOI: 10.3969/j.issn.1006-2084.2006.0 7.006.

[3] Xu Shanshan, Gu Xuefan, Pan Hui et al. Reference range s for serum IGF-1 and IGFBP-3 levels in Chinese children d uring childhood and adolescence [J]. Endocrine Journal, 2010, 57(3): 221-228. DOI: 1 10.1507/endocrj.k09e-200.

CE

~

Hunan Kangxin Biotechnology Co., Ltd.

Address: Room 301, 3rd Floor, Warehouse 5#, Block 6#, Xiangtan Comprehensive Free Trade Zone, 46#, Free Trade Road, Peace Street, Xiangtan Economic Development Zone, 411215, Xiangtan, PEOPLE'S REPUBLIC OF CHINA Tel: +86 28 85155537 Website: www.vacurebiotech.com E-mail: info@vacurebiotech.com

EC REP CMC Medical Devices & Drugs S.L.

Address: C/Horacio Lengo Nº 18, CP 29006, Málaga-Spain Tel: +34 951 214054 Fax: +34 952 330100 E-mail: info@cmcmedicaldevices.com

Revision history

Version	Revision date	Change description
V01	2022-05-05	Initial